Arcoma Toekomstige groei
Future criteriumcontroles 3/6
Arcoma is forecast to grow earnings and revenue by 7.9% and 8.3% per annum respectively. EPS is expected to grow by 9% per annum. Return on equity is forecast to be 20.3% in 3 years.
Belangrijke informatie
7.9%
Groei van de winst
9.0%
Groei van de winst per aandeel
| Medical Equipment winstgroei | 32.8% |
| Inkomstengroei | 8.3% |
| Toekomstig rendement op eigen vermogen | 20.3% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 25 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Solid Earnings Reflect Arcoma's (STO:ARCOMA) Strength As A Business
Aug 22
At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?
Aug 07Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?
Apr 26Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price Bounce
Feb 06Is Arcoma (STO:ARCOMA) A Risky Investment?
Jan 15We Think Arcoma (STO:ARCOMA) Is Taking Some Risk With Its Debt
Sep 11Is Arcoma (STO:ARCOMA) Using Too Much Debt?
Jun 08Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?
Apr 27Does Arcoma (STO:ARCOMA) Have A Healthy Balance Sheet?
Dec 22Is Arcoma (STO:ARCOMA) Using Too Much Debt?
May 03These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Extensively
Oct 28Is Arcoma (STO:ARCOMA) A Risky Investment?
Mar 17Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?
Feb 04Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?
Jan 14
Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Jan 12These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably Well
Dec 17Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)
Nov 21Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 207 | 17 | 17 | 22 | 1 |
| 12/31/2025 | 194 | 15 | 12 | 17 | 1 |
| 12/31/2024 | 178 | 16 | 8 | 13 | 1 |
| 9/30/2024 | 171 | 13 | 24 | 28 | N/A |
| 6/30/2024 | 175 | 13 | 19 | 22 | N/A |
| 3/31/2024 | 172 | 9 | 19 | 21 | N/A |
| 12/31/2023 | 163 | 3 | 17 | 19 | N/A |
| 9/30/2023 | 153 | 0 | -1 | 3 | N/A |
| 6/30/2023 | 146 | 0 | -2 | 3 | N/A |
| 3/31/2023 | 138 | 1 | 2 | 8 | N/A |
| 12/31/2022 | 125 | 2 | -4 | 0 | N/A |
| 9/30/2022 | 105 | -6 | 5 | 8 | N/A |
| 6/30/2022 | 99 | -10 | 0 | 2 | N/A |
| 3/31/2022 | 105 | -11 | -11 | -8 | N/A |
| 12/31/2021 | 117 | -7 | -6 | -2 | N/A |
| 9/30/2021 | 126 | -6 | -10 | -7 | N/A |
| 6/30/2021 | 125 | -2 | -7 | -2 | N/A |
| 3/31/2021 | 121 | -1 | -6 | 0 | N/A |
| 12/31/2020 | 117 | 1 | -5 | 7 | N/A |
| 9/30/2020 | 122 | 8 | -14 | 2 | N/A |
| 6/30/2020 | 130 | 10 | 3 | 20 | N/A |
| 3/31/2020 | 132 | 10 | 2 | 18 | N/A |
| 12/31/2019 | 134 | 7 | 0 | 11 | N/A |
| 9/30/2019 | 133 | 5 | 5 | 11 | N/A |
| 6/30/2019 | 132 | 2 | -3 | 2 | N/A |
| 3/31/2019 | 129 | 1 | 1 | 4 | N/A |
| 12/31/2018 | 119 | -2 | -1 | 0 | N/A |
| 9/30/2018 | 111 | -1 | -3 | -1 | N/A |
| 6/30/2018 | 98 | -6 | N/A | -11 | N/A |
| 3/31/2018 | 94 | -10 | N/A | -8 | N/A |
| 12/31/2017 | 92 | -10 | N/A | -9 | N/A |
| 9/30/2017 | 98 | -9 | N/A | 0 | N/A |
| 6/30/2017 | 108 | -4 | N/A | 3 | N/A |
| 3/31/2017 | 106 | -5 | N/A | 0 | N/A |
| 12/31/2016 | 102 | -12 | N/A | -5 | N/A |
| 9/30/2016 | 106 | -12 | N/A | -12 | N/A |
| 6/30/2016 | 105 | -13 | N/A | -9 | N/A |
| 3/31/2016 | 104 | -15 | N/A | -17 | N/A |
| 12/31/2015 | 123 | -6 | N/A | -5 | N/A |
| 9/30/2015 | 117 | -6 | N/A | -4 | N/A |
| 6/30/2015 | 119 | -5 | N/A | -2 | N/A |
| 3/31/2015 | 133 | 1 | N/A | 5 | N/A |
| 12/31/2014 | 130 | 1 | N/A | -1 | N/A |
| 9/30/2014 | 134 | -7 | N/A | -1 | N/A |
| 12/31/2013 | 108 | -14 | N/A | -12 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: ARCOMA's forecast earnings growth (7.9% per year) is above the savings rate (1.1%).
Winst versus markt: ARCOMA's earnings (7.9% per year) are forecast to grow slower than the Swedish market (15.7% per year).
Hoge groeiwinsten: ARCOMA's earnings are forecast to grow, but not significantly.
Omzet versus markt: ARCOMA's revenue (8.3% per year) is forecast to grow faster than the Swedish market (0.01% per year).
Hoge groei-inkomsten: ARCOMA's revenue (8.3% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: ARCOMA's Return on Equity is forecast to be high in 3 years time (20.3%)